Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial

Autor:	Atsushi Taniguchi, Kazuki Koiwai, Takashi Kadowaki, Masakazu Haneda, Hans-Juergen Woerle, Henning Rattunde, Nobuya Inagaki, Yasuo Terauchi, Uli C. Broedl
Rok vydání:	2014
Předmět:	Blood Glucose Male medicine.medical_specialty endocrine system diseases Blood Pressure Placebo Gastroenterology Double-Blind Method Glucosides Japan Weight loss Diabetes mellitus Internal medicine Weight Loss medicine Clinical endpoint Empagliflozin Humans Hypoglycemic Agents Pharmacology (medical) Benzhydryl Compounds Adverse effect Aged Glycated Hemoglobin Dose-Response Relationship Drug business.industry General Medicine Middle Aged medicine.disease Blood pressure Treatment Outcome Tolerability Diabetes Mellitus Type 2 Female medicine.symptom Drug Monitoring business
Zdroj:	Advances in therapy. 31(6)
ISSN:	1865-8652
Popis:	This study was designed to determine the efficacy and tolerability of empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus (T2DM). Patients with glycosylated hemoglobin (HbA1c) ≥7.0–≤10% were randomized via an interactive web response system, and treated double-blind with empagliflozin 5, 10, 25, 50 mg, or placebo once daily for 12 weeks. The primary endpoint was change from baseline in HbA1c at week 12. Other endpoints included percentage of patients with HbA1c
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19a3b51214c223711941b91d86b2be9d https://pubmed.ncbi.nlm.nih.gov/24958326 Zobrazit plný text záznamu Full text from SpringerLink